Last reviewed · How we verify

Ncardipine Hydrochloride Injection — Competitive Intelligence Brief

Ncardipine Hydrochloride Injection (Ncardipine Hydrochloride Injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dihydropyridine calcium channel blocker. Area: Cardiovascular.

phase 3 Dihydropyridine calcium channel blocker L-type voltage-gated calcium channel Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Ncardipine Hydrochloride Injection (Ncardipine Hydrochloride Injection) — Nanjing Yoko Biomedical Co., Ltd.. Nicardipine hydrochloride is a dihydropyridine calcium channel blocker that inhibits calcium influx into vascular smooth muscle cells, causing vasodilation and reducing blood pressure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ncardipine Hydrochloride Injection TARGET Ncardipine Hydrochloride Injection Nanjing Yoko Biomedical Co., Ltd. phase 3 Dihydropyridine calcium channel blocker L-type voltage-gated calcium channel
Amlodipine plus Metformin Amlodipine plus Metformin Third Military Medical University marketed Combination therapy: calcium channel blocker + biguanide antidiabetic L-type voltage-gated calcium channels (amlodipine); AMP-activated protein kinase and mitochondrial glycerophosphate dehydrogenase (metformin)
Levamlodipine besylate Levamlodipine besylate Jiangsu Simcere Pharmaceutical Co., Ltd. marketed Dihydropyridine calcium channel blocker L-type voltage-gated calcium channel
Ramipril + Felodipine Ramipril + Felodipine Sanofi marketed ACE inhibitor + calcium channel blocker combination Angiotensin-converting enzyme (ACE) and L-type voltage-gated calcium channels
olmesartan medoxomil / amlodipine or azelnidipine olmesartan medoxomil / amlodipine or azelnidipine COLM Study Research Organization marketed Angiotensin II receptor blocker / Calcium channel blocker combination Angiotensin II type 1 receptor (AT1R); L-type voltage-gated calcium channels
Losartan (+) amlodipine Losartan (+) amlodipine Organon and Co marketed Angiotensin II receptor blocker + calcium channel blocker combination AT1 receptor (losartan); L-type voltage-gated calcium channel (amlodipine)
nifedipine CR tablets (Adalat) nifedipine CR tablets (Adalat) Shanghai Shyndec Pharmaceutical Co., Ltd. marketed Calcium channel blocker (dihydropyridine) L-type voltage-gated calcium channel

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dihydropyridine calcium channel blocker class)

  1. Bayer · 1 drug in this class
  2. CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · 1 drug in this class
  3. Haseki Training and Research Hospital · 1 drug in this class
  4. Jiangsu Simcere Pharmaceutical Co., Ltd. · 1 drug in this class
  5. Korea University Guro Hospital · 1 drug in this class
  6. Nanjing Yoko Biomedical Co., Ltd. · 1 drug in this class
  7. Organon and Co · 1 drug in this class
  8. Pfizer Inc. · 1 drug in this class
  9. University Hospital Hradec Kralove · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ncardipine Hydrochloride Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/ncardipine-hydrochloride-injection. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: